amyloid

Lilly’s adcomm win shows amyloid and tau will likely dominate Alzheimer’s — for now
Pharma Voice
Thu, 06/13/24 - 10:50 am
Eli Lilly
Alzheimer's disease
donanemab
amyloid
tau
FDA guidelines consider amyloid reduction 'reasonably likely' to predict Alzheimer's benefit
Fierce Biotech
Tue, 03/12/24 - 11:34 am
Biogen
Eisai
Aduhelm
FDA
Alzheimer's disease
amyloid
Eli Lilly
donanemab
Biotech AltPep scores around $53m in Series B funding round
Pharmaceutical Business Review
Fri, 06/23/23 - 09:56 am
AltPrep
funding
amyloid
5 takeaways from the FDA's high-stakes meeting for Biogen's Alzheimer's drug
BioPharma Dive
Mon, 11/9/20 - 08:56 pm
Biogen
FDA
Alzheimer's disease
aducanumab
clinical trials
amyloid
Biogen and Eisai trial drug in asymptomatic Alzheimer’s disease
Pharmaforum
Tue, 07/14/20 - 10:31 am
Biogen
Eisai
Alzheimer's disease
amyloid
BAN2401
clinical trials